CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Cephalon Inc. v. Unimark Remedies Ltd.

1:15-cv-00117

Overview

Case Number 1:15-cv-00117
Filing Date 2015-02-02
Status Terminated
Termination Date 2015-07-28
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Unimark Remedies Ltd. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Cephalon Inc. Operating Company

Represented By

1 Attorneys Listed

Douglas Edward McCann

Fish & Richardson, P.C.

Tel: +1 (302) 652-5070
Fax: +1 (302) 652-0607

222 Delaware Avenue, 17th Floor, P.O. Box 1114

Plaintiff

Teva Sante SAS Operating Company

Represented By

1 Attorneys Listed

Douglas Edward McCann

Fish & Richardson, P.C.

Tel: +1 (302) 652-5070
Fax: +1 (302) 652-0607

222 Delaware Avenue, 17th Floor, P.O. Box 1114

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 11 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (11): FR πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7132570
Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Filed: 2003-12-18
Issued: 2006-11-07
Expired (Term Ended)
Expires: 2023-12-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Docket Entries

(12 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against Unimark Remedies Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1667279.) - filed by Cephalon Inc., Teva Sante SAS. (Attachments: # 1 Civil Cover Sheet)(dmp, ) (Entered: 02/03/2015)

Entry #1 • 2015-02-02
1
Pleading / Complaint

COMPLAINT filed with Jury Demand against Unimark Remedies Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1667279.) - filed by Cephalon Inc., Teva Sante SAS. (Attachments: # 1 Civil Cover Sheet)(dmp, ) (Entered: 02/03/2015)

Entry #1 • 2015-02-02
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 02/03/2015)

Entry #2 • 2015-02-02
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/22/2014. Date of Expiration of Patent: 12/18/2023 AND 06/18/2024.Thirty Month Stay Deadline: 6/22/2017. (dmp, ) (Entered: 02/03/2015)

Entry #3 • 2015-02-02
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,132,570 B2;. (dmp, ) (Entered: 02/03/2015)

Entry #4 • 2015-02-02
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc